RLT
RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
View More
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Emily MenendezRLT | June 25, 2025
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
Jessica GangaRLT | June 25, 2025
New research explores the prognostic potential of LuPSMA-SPECT/CT with RECIP 1.0 in patients with advanced prostate cancer.
Scott Tagawa, MD, MS, FACPRLT | June 5, 2025
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Scott Tagawa, MD, MS, FACPRLT | June 5, 2025
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Scott Tagawa, MD, MS, FACPRLT | June 5, 2025
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Scott Tagawa, MD, MS, FACPRLT | June 5, 2025
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Zeynep Irem Ozay, MDRLT | June 4, 2025
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
Bastiaan Privé, MDRLT | June 2, 2025
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Louise Emmett, MDRLT | May 31, 2025
Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
Emily MenendezRLT | May 29, 2025
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
Emily MenendezRLT | May 23, 2025
18F-flotufolastat-PET can help determine severe hematologic toxicity in patients with mCRPC who are treated with 177Lu.
Scott Tagawa, MD, MS, FACPProstate Cancer | April 4, 2025
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Amar Kishan, MDRLT | April 3, 2025
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
Emily MenendezCRPC | March 31, 2025
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Michael Morris, MDmHSPC | March 31, 2025
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICDRLT | March 31, 2025
Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.
Jérémie Calais, MD, PhDRLT | March 26, 2025
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Emily MenendezRLT | March 7, 2025
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Advertisement
Advertisement